Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors.
Alessandro AlaimoMarco LorenzoniPaolo AmbrosinoArianna BertossiAlessandra BisioAlice MacchiaEugenio ZoniSacha GenovesiFrancesco CambuliVeronica FolettoDario De FeliceMaria Virginia SoldovieriIlaria MoscaFrancesco GandolfiMatteo BrunelliGianluca PetrisAnna CeresetoAlvaro VillarroelGeorge ThalmannFrancesco Giuseppe CarboneMarianna Kruithof de JulioMattia BarbareschiAlessandro RomanelMaurizio TaglialatelaAndrea LunardiPublished in: Cell death & disease (2020)
Therapy resistance is a major roadblock in oncology. Exacerbation of molecular dysfunctions typical of cancer cells have proven effective in twisting oncogenic mechanisms to lethal conditions, thus offering new therapeutic avenues for cancer treatment. Here, we demonstrate that selective agonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), a cation channel characteristic of the prostate epithelium frequently overexpressed in advanced stage III/IV prostate cancers (PCa), sensitize therapy refractory models of PCa to radio, chemo or hormonal treatment. Overall, our study demonstrates that pharmacological-induced Ca2+ cytotoxicity is an actionable strategy to sensitize cancer cells to standard therapies.
Keyphrases
- prostate cancer
- palliative care
- benign prostatic hyperplasia
- healthcare
- ionic liquid
- chronic obstructive pulmonary disease
- high glucose
- stem cells
- transcription factor
- diabetic rats
- quality improvement
- mesenchymal stem cells
- risk assessment
- skeletal muscle
- pain management
- intensive care unit
- drug induced
- polycystic ovary syndrome
- chronic pain
- adipose tissue
- human health
- cerebral ischemia
- cell therapy
- binding protein
- health insurance
- replacement therapy
- bone marrow
- extracorporeal membrane oxygenation